newsfilter
← Latest News
GlobeNewswire·

Celyad Oncology Announces First Patient Dosed in KEYNOTE-B79 Phase 1b Trial

KEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) ASCO-GI conference abstract accepted that highlights KEYNOTE-B79 clinical trial design